These webinars are organised by the APSAD Smoking and Vaping Cessation Professionals (ASVCP) Special Interest Group for APSAD members, providing the opportunity to share information and knowledge through regular contact and webinars. The aim is the promotion of optimal smoking cessation practice in Australasia by trained health professionals incorporating evidence-based practice with an ongoing learning objective.
Membership of the ASVCP-SIG is open to APSAD members with an interest in Smoking and Vaping Cessation. For information contact Membership Services at This email address is being protected from spambots. You need JavaScript enabled to view it..
Coming Up in the ASVCP Webinar Series
March Webinar
Information coming soon.
You can watch the 2025 webinar series collection here.
Individual webinars are available below and go back to 2018.
|
Registration Terms and Conditions Any persons affiliated with tobacco entities (current, in the past, or have future plans), tobacco lobbyists, either professionally or on a personal basis, will be ineligible to attend or present at any APSAD webinar or event. APSAD’s policy is aligned with the World Health Organization’s Framework Convention on Tobacco Control, Article 5.3: There is a fundamental and irreconcilable conflict between the tobacco industry’s interest and public health policy interests. Registrations from such persons will be cancelled without notice. Paid registrations of such persons will not be refunded. |
|
Disclaimer The views expressed by presenters and speakers are not necessarily the views of APSAD, and the Society does not accept responsibility for any information, research, recommendation or advice presented. |
-----------------------------------------------------------------------------------------------
Watch ASVCP Webinars
Previous Recordings
February 2026 l Cytisine: The Comeback Compound in Cessation
This presentation explores cytisine, a long‑standing plant‑derived partial agonist of the nicotinic acetylcholine receptor that is experiencing renewed global interest as a cessation aid. The session begins with a brief historical overview, tracing cytisine’s origins from Eastern European use in the 1960s through to its modern resurgence as an affordable, evidence‑based pharmacotherapy. It then summarises the clinical evidence demonstrating cytisine’s effectiveness for smoking cessation, including large, randomised trials showing superiority to placebo and comparability or superiority to varenicline. Emerging findings on its potential role in vaping cessation are also discussed.
The presentation concludes with a practical focus on clinical application, covering dosing regimens, side‑effect profiles, patient suitability, and how cytisine can be integrated into routine tobacco dependence treatment pathways.
Presenter: Professor Hayden McRobbie, Professor of Population Health, Wolfson Institute of Public Health, Queen Mary University of London
January 2026 l Break the Habit Study (Vaping vs varenicline for smoking cessation among people experiencing social disadvantage: a consumer guided clinical trial)
Presenter: Saumya Bhatta, Clinical Trials Coordinator for the Tobbaco Research Group, NDARC, UNSW Sydney
September 2025 l Varenicline: It's better than you think
We'll ask these questions.
- Does Varenicline really work?
- How might it work?
- Does it interact with other drugs?
- Some clients say it causes them neuropsychiatric symptoms. Is this true?
- What about people with mental illness?
- What about people that are alcohol dependent?
- Dosing and administration, what's best practice?
- Any populations that should not be using it?
- Common side-effects and any simple steps to reduce them?
And...What the journal articles and text books won’t tell you
Presenter: James McLennan, State-Wide Training Coordinator - smoking and vaping cessation from Alcohol and Drug Service, St Vincent's Hospital Sydney
August 2025 l Information & Update Session: Credentialling process for Nicotine Treatment Specialists
This webinar will be a general information and update session on the credentialling process for Nicotine Treatment Specialists. This is a great opportunity to ask any questions and find out more about becoming a Nicotine Treatment Specialist!
Presenter: Professor Ryan Courtney, Program Lead Tobacco Research Group, National Drug & Alcohol Research Centre, University of New South Wales, Sydney; Associate Professor/ National Heart Foundation Future Leader Fellow; and ASVCP Chair
June 2025 l Smoking and Vaping Cessation in the Youth Custody Setting NSW
There are high rates of all smoking behaviours in young people entering youth custody. This presentation will provide recent data on rates of all smoking behaviours in young people on admission, and approaches to managing nicotine dependence in the smoke-free environment of youth justice.
Presenters:
Dr Leigh Haysom, Clinical Director Adolescent Health, Adolescent Health, Justice Health and Forensic Mental Health Network
Anna Barker, Staying Quit Senior Project Officer, Population and Preventive Health, Justice Health and Forensic Mental Health Network
May 2025 l Leveraging the new National Lung Cancer Screening Program for Smoking Cessation: Implications and Implementation
Australia’s National Lung Cancer Screening Program starts in July, for people with smoking history and at high risk of lung cancer but without any symptoms. In this webinar, A/Prof Marshall will provide an overview of the National Program and discuss opportunities to integrate smoking cessation into screening discussions. Dr White will examine the program’s implications for cessation services, with a particular focus on the role of Quitline in supporting individuals identified through screening. Webinar attendees will gain insights into best practices for leveraging lung cancer screening as a key moment for engaging smokers in evidence-based cessation support.
Presenters: Associate Professor Henry Marshall & Dr Kahren White
April 2025 l Smoking cessation and vaping cessation in New Zealand : Two community-based pragmatic trials to inform practice and policy.
Reduced harm e-cigarettes are endorsed by the Aotearoa New Zealand government as an effective smoking cessation treatment. Once people have fully switched to vaping, it's recommended that they then stop vaping (provided there is no risk of relapse back to smoking). This webinar will first present the results of 1 a large, pragmatic community-based trial undertaken in Aotearoa New Zealand, exploring the effectiveness of combining cytisine with nicotine e-cigarettes to quit smoking, compared to single product use. The rationale and design of a large, pragmatic community-based vaping cessation trial (currently underway in Aotearoa New Zealand) will also be discussed.
Presenters: Professor Natalie Walker, and Professor Chris Bullen.
March 2025 l Tackling Tobacco: Approaching 20 years of partnership with the community service sector
As the Tackling Tobacco program approaches its 20th year of implementation in NSW, this webinar will provide an overview of the program, including key milestones, contributions to the evidence base and the evolution of the program over time. The effectiveness of the program will be examined through the results of randomised controlled trials and case studies, with a focus on the impact the program has had in non-government alcohol and other drug services. Real-world examples of the program’s impact will be showcased, illustrating the practical applications of the implementation strategies and lessons learned from extensive program delivery across almost two decades.
Presenter: Laura Twyman, Program Lead, Tobacco Cessation, Tobacco Control Unit, Cancer Prevention and Advocacy Division, Cancer Council NSW
February 2025 l Interim evaluation of the Incentive to Quit (I2Q) pilot program for smoking and vaping cessation
The Incentive to Quit (I2Q) Pilot Program is a government-funded initiative aimed at reducing smoking and vaping rates among high-prevalence nicotine users in South Australia. Implemented across four health service groups in the Northern Adelaide Local Health Network (NALHN), the program offered financial incentives of up to $150 to encourage quit attempts and engagement with Quitline services.
This presentation will describe key findings such as participant reach; 3- and 6-month cessation rates and Quitline engagement for those who have completed this milestone; cost-effectiveness; implementation barriers and enablers; participant feedback; policy implications; and next steps.
Presenter: Kelsey Sharrad, PhD Candidate, School of Medicine, University of Adelaide; Research Coordinator, Department of Sleep and Respiratory Medicine, Women's and Children's Hospital; Senior Project Manager, Houd Research Group
November 2024 l Cytisine without prescription in Australia
Cytisine has recently been scheduled as a pharmacist-only medicine in Australia. This presentation provides an opportunity to understand what this means and what people can do to help get cytisine on the market in Australia.
Presenter: Dr Natalie Gauld, Director, Natalie Gauld Ltd
As requested by the presenter the recording will not available for this webinar.
September 2024 l Clinical use of biomarkers: Bringing precision medicine to smoking and vaping cessation
Presenter: Prof Renee Bittoun, Medical School, Notre Dame University and Nicotine Addiction Unit, Lifestyle Medicine, Avondale University, Sydney, NSW
Presenter: Michael Fitzpatrick, Senior Hospital Scientist, Department of Chemical Pathology, Royal Prince Alfred Hospital, Camperdown, NSW
August 2024 l Practices and insights from use of NRT products in research trials across community and health settings
This presentation will outline the use of nicotine replacement therapies as core smoking cessation intervention elements in a number of randomised controlled trials with high priority groups across various health and community setting types. Research lessons learned as well as perspectives and experiences from setting staff and volunteers will be presented.
Presenter: Dr Ashleigh Guillaumier, Senior Research Fellow, College of Medicine and Public Health, Flinders University
July 2024 l A content analysis of illicit tobacco-related crimes reported in Australian media
Australian survey and seizure data suggest a growing illicit tobacco market. As an illicit product, accurately tracking trends in illicit tobacco growing, manufacture and sales is challenging. This is the first study that has used media articles and government press releases to synthesise trends in Australia’s illicit tobacco market over the past two decades, and as such, represents the most comprehensive synthesis to date of illicit tobacco-related crimes in Australia. This presentation will explore and discuss these trends.
Presenter: Ms Isabel Meciar, PhD Candidate, NHMRC Centre of Research Excellence on Achieving the Tobacco Endgame, The University of Queensland
June 2024 l Tobacco Use in Drug and Alcohol Use Disorders: First cab off the rank or least of our problems
This webinar will cover the epidemiology and evidence base for treatment of tobacco use disorders in people with other substance use disorders. It will also cover important clinical considerations including drug-drug interactions and considerations in prioritisation of care.
Presenter: Dr Adam Pastor, Deputy Director Department Addiction Medicine, St Vincent's Hospital Melbourne
June 2024 l Trends in vaping and tobacco smoking: An Australian and Aotearoa New Zealand outlook
Presenters:
Professor Hayden McRobbie, National Drug & Alcohol Research Centre, University of New South Wales, Sydney; and Regional Director, Northern National Public Health Service, Health Board New Zealand,
Dr Ryan Courtney, Program Lead Tobacco Research Group, National Drug & Alcohol Research Centre, University of New South Wales, Sydney; Associate Professor/ National Heart Foundation Future Leader Fellow; and ASVCP Chair
April 2024 | An update on the Royal Australian College of General Practitioners (RACGP) guidance for clinicians on Therapeutic Vaping
This presentation will critique recent changes to regulation on access to vaping products and discuss use of therapeutic vaping for treatment of nicotine dependence.
Presenter: Professor Nicholas Zwar, Executive Dean, Faculty of Health Sciences and Medicine, Bond University
March 2024 | Reducing e-cigarette use among young people in NSW - social marketing campaign
This presentation will provide an overview of the NSW social marketing campaign to reduce e-cigarette use among young people (14-24 years). The presentation will focus on research and insights for campaign development
Presenters: Kate Reakes, Manager, Cancer Prevention, Cancer Screening & Prevention, Cancer Institute NSW, and Dr Sandra Rickards, Team Leader, Research & Evaluation, Cancer Screening & Prevention, Cancer Institute NSW
No recording availble for this webinar.
February 2024 | Intensive tobacco treatment incorporating contingency management for women attending substance use in pregnancy antenatal services. Is it feasible?
Pregnant women who use tobacco and other psychoactive substances are a high-priority group. Typically, considerable resources are devoted to preventing other substance use, but most women will continue to smoke tobacco throughout their pregnancy and beyond. This webinar describes the feasibility of an intensive tobacco treatment incorporating contingency management, nicotine replacement therapy and behavioural counselling into treatment for women attending substance use in pregnancy antenatal services. Included are results from the pilot trial including a cost-consequence analysis, and qualitative analysis of acceptability from the client and clinician perspective.
Presenter: Dr Melissa Jackson, Clinical Trial Coordinator, Drug and Alcohol Clinical Services Research Unit, Hunter New England Local Health District, NSW
October 2023 | Generation Vape: The explosive rise in youth vaping in Australia
Presenter: Becky Freeman, Associate Professor Becky Freeman leads a program of research focused on countering the commercial determinants of health, including tobacco, e-cigarettes, and processed food.
| WATCH THIS WEBINAR |
September 2023 | Unlocking options: The changing landscape of smoking cessation medications’ availability in Australia
Presenter: Deepali Gupta, is an advanced pharmacist, working across many complex clinical areas at QEII Hospital in Brisbane| WATCH THIS WEBINAR |
AUGUST 2023 | The teachable moment of lung cancer screening: stakeholder views and significant opportunities to offer cessation support
Presenter: Nathan Harrison PhD Candidate and Senior Research OfficerPublic Health Discipline and National Centre for Education and Training on Addiction (NCETA), College of Medicine and Public HealthFlinders University| WATCH THIS WEBINAR |
June 2023 |Vaping Trends
Presenter Prof Ryan Courtney| WATCH THIS WEBINAR |
May 2023 | The patient experiences of adults with Chronic Obstructive Pulmonary Disease (COPD) in Australian general practice
Study findings from four studies, conducted as part of the PhD thesis will be discussed. The studies broadly seek to describe and synthesise the experience of care for adults with COPD and focus on patients seeking care in the community, who continue to smoke. The first study was a secondary analysis of data from an online, nationwide survey. Next, a meta-ethnographic review of published qualitative studies and a mixed-methods narrative rapid review that described patient experiences during the COVID-19 pandemic. Finally, an Interpretative Phenomenological Analysis (IPA) to explore the healthcare experiences of patients with doctor diagnosed COPD in primary care.Presenter: Sanduni Madawala, Research Fellow/Research Assistant Department of General Practice Monash University| WATCH THIS WEBINAR |
April 2023 | Why has Australia failed to implement tobacco endgame policies and what might precipitate policy adoption?
Modelling indicates that tobacco endgame policies will rapidly reduce smoking and improve health equity. Andrew’s PhD study uses applied policy research to explore themes and framing of tobacco endgame policies for Australia. Approaches include comparative policy analysis, and analysis of media articles, public health submissions and interviews with policy stakeholders. Dominant public health models and theories of the policy process inform the research designs and data analysis.
Presenter: Andrew Perusco, PhD Student/ Sir Roland Wilson Scholar Team/Department National Centre for Aboriginal and Torres Strait Islander Wellbeing Research/ NHMRC Centre of Research Excellence on Achieving the Tobacco Endgame
March 2023 | High-dose transdermal nicotine replacement therapy: Risk of overdose or best practice?
Nicotine Replacement Therapy (NRT) has been an approved first-line smoking cessation therapy for almost 40 years. When used in recommended doses, NRT increases the odds of a person quitting smoking. However, smokers range in nicotine plasma levels and some smokers are more highly dependent than others. So for a high nicotine dependent smoker, the recommended doses may be insufficient to manage withdrawals and “ replace” the nicotine.This presentation explores the evidence around using multiple patches concurrently, and provides some practical case studies illustrating how it can be approached.
Presenters: Prof Renee Bittoun Tobacco Treatment Specialist, Consultant, Professor, Nicotine Addiction Unit, Lifestyle Medicine, Avondale University, Australia, and the Medical School, University of Notre Dame, Australia,
Andrew Mark Health Promotion Officer, Illawarra Shoalhaven Local Health District
| WATCH THIS WEBINAR |
February 2023 | The cardiovascular risk & benefits of smoking cessation pharmacotherapies use among cardiac patients
This webinar reports the results of three population-based cohort studies. The first provides evidence on how the three smoking cessation pharmacotherapies available in Australia (NRT, varenicline and bupropion) compare to each other in terms of cardiovascular safety. The second describes the use of these pharmacotherapies among patients who hospitalised in NSW with major cardiovascular disease. Our third study compares the effectiveness of NRT and varenicline in preventing recurrent cardiovascular events.
Presenters: Dr Alys Havard, Senior Research Fellow, National Drug and Alcohol Research Centre and School of Population Health, UNSW Sydney
Dr Annelies Robijn, Postdoctoral Research Fellow National Drug and Alcohol Research Centre, UNSW Sydney.
| WATCH THIS WEBINAR |
January 2023 | Smoking Cessation for Hospitalised Patients - Do We Have Time to Intervene?
In the first ASCP webinar of 2023 Associate Professor Ben Kwan will review the concept of hospital based smoking intervention, different approaches and model of care. Along with the role of different health professional groups within the acute care setting to aid in smoking cessation.
Presenter A/Prof Benjamin Kwan, Senior Staff Specialist, St Vincent's Hospital, Sydney & Sutherland Hospital| WATCH THIS WEBINAR |
December 2022 | Let's talk about smoking Smokefree Healthcare in Mental Health Services
Mental health alcohol and other drug (MHAOD) services are well positioned to provide smoking cessation care to people experiencing mental illness however, the delivery of routine evidence-based care has not been easily achieved. This webinar will describe the practice change undertaken in Queensland to implement routine smoking cessation care across Queensland public adult MHAOD services and the partnership developed with Quitline Queensland to provide an intensive Quit program. The presentation will provide statewide outcomes, offer reflections on strengths and challenges, and provide a brief introduction to future initiatives.
Presenter: Sally Plever, is a Psychologist. She currently co-manages the Queensland Health Mental Health Clinical Collaborative (Qld MHCC), a statewide initiative for clinical service improvement in adult mental health, alcohol and other drug services
| WATCH THIS WEBINAR |
November 2022 | Escape the Vape: Supporting Adolescents and Young Adults Quit Vapes
To download a copy of the presentation slides, click here
For resources for clinicians working with adolescents, click here
August 2022 |What's in a vape: Implications for the regulation of electronic cigarettes in Australia
Australian regulation of electronic cigarettes and the scheduling of nicotine for use in these devices has recently changed (October 2021). Jody's research involves the examination of the content and toxicity of electronic cigarette liquids and aerosols.
Presenter: Dr Jody Moller (Morgan), is a lab-based toxicology researcher whose research interests sit at the intersection of analytical chemistry and public health with a focus on harm reduction methods. Her current research is focused on electronic cigarettes, cannabis and pill-testing, with particular emphasis on identification and quantification of chemical constituents in samples available to Australian consumers.
| WATCH THIS WEBINAR |
June 2022 | Indigenous excellence in reducing smoking prevalence
Presenter: Dr Raglan Maddox’s (Modewa Clan, Papua New Guinea) program of research has focused on Indigenous tobacco.
There have been significant declines reducing tobacco use. In 2018–19, 40.2% of Aboriginal and Torres Strait Islander adults were smoking daily. This reflects a 9.8% absolute decrease in prevalence since 2004–05 (50.0%) and representing almost 50,000 fewer Aboriginal and Torres Strait Islander smokers than if prevalence remained unchanged. What lessons can we take from Indigenous tobacco control since 2004-05 and where to from here?
May 2022 | Smoke in clinician's eyes - missing foetal nicotine exposure
Presenter:Angela Ratsch is a registered nurse and midwife with a particular interest in the neonatal outcomes from exposure to tobacco and nicotine pre-conceptionally and during gestation
In Australia, the maternal use of cigarettes is recorded twice across the nine months of pregnancy, however the maternal use of NRT and/or other cigarette and nicotine alternatives such as e-cigarettes, heat-not-burn tobacco, nicotine spray, mist, lozenges, gum and patches, hookahs, and chewed tobacco products is not collected. In addition, the paternal and house-hold use of tobacco and nicotine products is not recorded, thus maternal second-hand tobacco and nicotine exposure is not captured. This knowledge vacuum results in maternal and foetal tobacco and nicotine exposure misclassification and ramifications in the estimation of adverse maternal, paternal, foetal and neonatal outcomes from tobacco and nicotine exposure.
April 2022 | 5 risk free behavioural strategies to manage cravings quickly
Presenter: James McLennan, State-Wide Smoking Cessation Training Co-ordinator, Alcohol and Drug Service, St Vincent’s Hospital, Sydney
Do you have clients and patients struggling when they experience cravings? Are you to finding it hard to offer practical, realistic strategies that work when cravings arise?
Here we inform of:
-
Five strategies that are risk free, cheap or cost free
-
Strategies that are easy to learn and apply yet grounded in science
-
Strategies that you can easily teach even if you are time-limited
March 2022 | An update on the Royal Australian College of General Practitioners (RACGP) guidance on the role of Nicotine Vaping Products in smoking cessationPresenter:
This presentation will critique new changes to the regulation of nicotine as per new rescheduling of nicotine e-liquids and outline revised recommendations and practice points.
Presenter: Professor Nick Zwar, Bond University and Chair of Expert Advisory Group for the publication An update on the Royal Australian College of General Practitioners (RACGP) guidance for smoking cessation.
| WATCH THIS WEBINAR |
August 2020 | An Evaluation of Online and Automated Smoking Cessation Programs
Presenter: Prof Ron Borland, Deputy Director, Melbourne Centre for Behaviour Change, School of Psychological Sciences, University of Melbourne
| WATCH THIS WEBINAR |
This NHMRC-funded research used linked pharmaceutical claims and administrative health data for all women who gave birth in New South Wales and Western Australia between 2004 and 2012 to examine the extent to which prescription NRT patches, bupropion and varenicline are used during pregnancy. To examine the effectiveness of these medicines during pregnancy, the smoking cessation rates associated with varenicline relative to NRT patch use was measured. The risk and benefits associated with these medicines in pregnancy was assessed by comparing the rate of adverse birth outcomes among women who used prescription NRT patches, bupropion or varenicline with the rate among women who smoked but did not receive any of these medicines.
Presenter: Alys Havard, Senior Research Fellow, Centre for Big Data Research in Health, University of NSW
| WATCH THIS WEBINAR |
Presenter: Prof Matthew Peters, Respiratory Physician and Head of Respiratory Medicine at Concord Hospital
| WATCH THIS WEBINAR |
Effective smoking cessation care (SCC) can save unnecessary loss of lives and smoking-related life long morbidity. The urgency of quitting smoking during pregnancy cannot be emphasised enough. Therefore, we put our effort to enhance SCC for pregnant Indigenous Australian women to support them to quit smoking for themselves and their families. Our research shows that smoking by Indigenous people is often influenced by numerous contextual, immediate social surroundings and personal factors, requiring SCC to be orchestrated at multiple levels and to be comprehensive. This presentation will be from Associate Prof Gillian Gould and members of her team to present their research on multiple aspects for interventions to address some of the major barriers around SCC. Ms Tabassum Rahman will present her systematic review about how the socio-ecological model can be applied to the barriers and enablers on system, health service, community and individual levels for the topic. A/Prof Gould will present the phased development and trials about the SISTAQUIT intervention (formerly ICAN QUIT in Pregnancy) that included an online training package for health professionals providing care to pregnant and postnatal Indigenous women, patient resources and free oral nicotine replacement therapy (NRT). A successful pilot study led to the randomised controlled trial of SISTAQUIT (Supporting Indigenous Smokers To Assist Quitting) and a national roll-out of the SCC care package as iSISTAQUIT, accompanied by a social media campaign. Dr Pari Eftekhari will present her research plan to engage family members, especially partners, in smoking cessation in pregnancy. Her research will explore partners perspectives to smoking cessation in pregnancy through our qualitative research project PAPAS. We will further outline a promising individual and community-based approach using the new MAMA-Empower Health App. Our collective goal is to make smoking cessation easier, more effective and relevant for Indigenous Australian women. The team will outline ways that the ASCP SIG could become involved in this research.
Presenters: A/Prof Gillian Gould, GP & Tobacco Treatment Specialist; Tabassum Rahman, PhD candidate; Dr Parivash Eftekhari, post-doctoral researcher and pharmacist, University of Newcastle; Allison Hart, Aboriginal Research Assistant & Cultural Liaison Officer Isistaquit
| WATCH THIS WEBINAR |
December 2019 |What is EVALI? What we do and do not know about the vaping lung cases in the USA
In April 2019, the first case was reported of what quickly became a high number of lung damage cases that appeared to be linked to the use of e-cigarettes in the USA. By now over 2000 cases have been reported, including 34 deaths, and the condition has been given a name: “e-cigarette or vaping product use associated lung injury” (EVALI). All cases have been reported in the US and the CDC, FDA and state health authorities have been conducting investigations into causes. The latest advice based on those investigations is that it seems that EVALI is linked to street-bought tetrahydrocannabinol (THC) vaping, with vitamin E acetate, used as a cutting agent, implicated. It appears that nicotine vaping is not associated with EVALI.
This presentation will provide an overview of the EVALI “outbreak”, placing it in the context of the research evidence of the safety of nicotine vaping, the communications and media reporting used to inform the public about EVALI, and the potential consequences of misinformation.
Presenter: Prof Billie Bonevski, UON Women in Science Chair, Faculty of Health and Medicine, University of Newcastle
| WATCH THIS WEBINAR |
The effects of e-cigarette vaping on lung pathophysiology are slowly emerging which counter the unsupported claims of the nicotine/tobacco industry that electronic cigarettes are relatively safe. A single session of e-cigarette vaping has been shown to negatively affect lung function which is accentuated in asthmatics. Vaping has now also been linked to an increase in the risk of pneumonias, and in a mouse model e-cigarette vapour exposure has been shown to induce systemic inflammation and multi-organ fibrosis. This presentation will discuss the effects of electronic devices on lung health, supported by our own lab-based studies. This is important so that Australians are better informed when it comes to the safety of these newer devices and will help accelerate research efforts and allow health agencies to take evidence based regulatory decisions.
Presenter: Dr Sukhwinder Sohal, University of Tasmania, Launceston
| WATCH THIS WEBINAR |
In this webinar, we bring together our extensive research findings as well as world studies to provide an overview of what women are experiencing - what the evidence is saying – and where to from here, in order to reduce the harms of smoking among pregnant women. Hear from GP research fellow and Tobacco Treatment Specialist A/Prof Gillian Gould, and Dr Ratika Kumar a dentist specialising in smoking cessation research in high-priority populations.
Presenter: A/Prof Gillian Gould, and Ratika Kumar, University of NewcastleSmoking in pregnancy is a well-known risk factor for both maternal and child health in the short as well as long term. Considering the limited research in this area and the fact that more than half of the women who smoke are not able to give up smoking during pregnancy, harm minimisation (harm reduction) options are desired. Women report they receive mixed messages about quitting versus cutting down in pregnancy from their healthcare providers.
| WATCH THIS WEBINAR |
Deepali will look at the evidence for cardio vascular concerns vs benefits of medications used for smoking cessation with a focus also in patients with cardiac disease. Come for an open discussion to discuss your concerns in managing smoking cessation in a patient with cardiac disease.
Presenter: Deepali Gupta, Senior Pharmacist, Preventative Team PAH
| WATCH THIS WEBINAR |
Shared Medical Appointments (SMAs), or group consultations are: “… a series of individual office visits (billable at individual rates) sequentially attending to each patient’s unique medical needs individually, but in a supportive group setting where all can listen, interact, and learn.” SMAs have been successfully used in chronic diseases such as Obesity and Diabetes. This presentation will describe a project that engages GPs in smoking cessation and relapse prevention using the SMA model.
Presenters: Prof Garry Egger, Professor of Lifestyle Medicine, is well known for his Gut Busters series and his world leadership in Lifestyle Medicine and A/Prof Renee Bittoun, Founding Editor-in-Chief The Journal of Smoking Cessation, Cambridge University Press
| WATCH THIS WEBINAR |
Presenter: Dr Rodrigo Ramalho, Psychiatrist and Academic at the University of Auckland
| WATCH THIS WEBINAR |
Tanya is a medicinal chemist-turned-clinical researcher for the Airways Physiology and Imaging Group at the Woolcock Institute of Medical Research and Concord Hospital. Her area of research includes respiratory physiology in both Smoking and Asthma.
Presenter: Tanya Badal, Research Assistant, Woolcock Institute of Medical Research
| WATCH THIS WEBINAR |
January 2019 | Targeted and collective action on tobacco control leads to shifts in tobacco management and smoking cessation
| WATCH THIS WEBINAR |
Presenter: Dr Ryan Courtney, National Health and Medical Research Council Career Development Fellow at UNSW, National Drug and Alcohol Research Centre
| WATCH THIS WEBINAR |
| WATCH THIS WEBINAR |
| WATCH THIS WEBINAR |
For further details on the ASCP-SIGs, visit our webpage.
The views expressed by presenters and speakers are not necessarily the views of APSAD, and the Society does not accept responsibility for any information, research, recommendation or advice presented.